Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Cellular Immunotherapy Market Size And Revenue Outlook Through 2030
The cellular immunotherapy market has shown rapid expansion recently. It is anticipated to increase from $6.56 billion in 2025 to $7.48 billion in 2026, with a compound annual growth rate (CAGR) of 14.1%. The market’s past growth is attributable to the success of early car-t therapies, unmet oncology needs, growth in research funding, regulatory approvals, and academic-industry collaboration.
The cellular immunotherapy market is projected to experience substantial expansion in the coming years, reaching $12.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.7%. This growth during the forecast period is primarily driven by factors such as the expansion of therapies into solid tumors, advancements in NK cell therapy, the development of scalable manufacturing processes, favorable regulatory environments, and increased financial commitment to oncology. Key trends anticipated for this period involve the swift rise of CAR-T cell therapies, the broadening application of allogeneic cell therapies, their increased utilization in treating hematologic malignancies, breakthroughs in T cell engineering, and a surge in clinical trial engagements.
Get A Free Sample Report With In-Depth Market Insights:
Cellular Immunotherapy Market Growth Factors Behind Sustained Expansion
The expansion of the cellular immunotherapy market is anticipated to be fueled by the increasing occurrence of cancer. Cancer is defined as a cluster of diseases characterized by the unrestrained proliferation and dissemination of abnormal cells throughout the body. The uptick in cancer prevalence is largely attributed to an aging global population, various lifestyle choices, and enhancements in diagnostic and screening protocols. Moreover, environmental exposures and genetic predispositions contribute significantly to the rising incidence rates. Cellular immunotherapy operates by strengthening the immune system’s response against cancer through the targeted destruction of tumor cells, consequently improving patient survival rates. This therapeutic strategy, when integrated with other treatments, holds the promise of decreasing both new cancer cases and their recurrence. For instance, in March 2024, MAC Clinical Research, a UK-based cancer research organization, reported that the estimated number of people living with cancer in the United Kingdom is expected to climb from around 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the escalating prevalence of cancer is undeniably propelling the growth within the cellular immunotherapy market.
Cellular Immunotherapy Market Segment Analysis And Revenue Potential
The cellular immunotherapy market covered in this report is segmented –
1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications
Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy
2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications
Cellular Immunotherapy Market Industry Trends Fueling Future Revenue Growth
Leading companies in the cellular immunotherapy market are focused on developing technological advancements, such as immunotherapy, to enhance treatment efficacy and expand their applications. Their efforts are directed towards personalized medicine, combination therapies, and scalable manufacturing to improve patient outcomes. Immunotherapy itself is a medical approach that utilizes the body’s immune system to fight diseases, especially cancer. This can involve boosting natural immune responses or delivering targeted therapies to strengthen immune activity against specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, highlighted CAR-T cell therapy. This revolutionary cancer treatment uses genetically engineered T cells to specifically target and destroy cancer cells, providing a personalized approach. It offers durable remission rates, particularly for resistant blood cancers, while minimizing damage to healthy tissues.
Cellular Immunotherapy Market Key Players Shaping Industry Direction
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation
View The Full Cellular Immunotherapy Market Report:
Cellular Immunotherapy Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model